Evidence-based medicine synopsis of the SURMOUNT-5 trial, confirming that tirzepatide produced significantly greater weight loss than semaglutide at 72 weeks in adults with obesity without T2DM. Summarizes the key comparative trial result in an accessible format for practitioners. Provides primary care and non-specialist clinicians with a concise evidence summary of the landmark head-to-head superiority evidence for tirzepatide over semaglutide in non-diabetic obesity—the pivotal finding supporting tirzepatide as the preferred pharmacotherapy when maximum weight reduction is the clinical goal.
Lesser, Lenard I